Curated News
By: NewsRamp Editorial Staff
June 20, 2024

Clene Inc. Presents New Long-Term CNM-Au8 Treatment Results at European ALS Meeting

Reddit Discuss on RedditDiscuss on Substack SubstackView History of this news story on GitHub Github
Source News Release

TLDR

  • Investors in Clene (NASDAQ: CLNN) can potentially gain an advantage from the new long-term CNM-Au8 treatment results for survival and neurofilament light levels.
  • The presentation data highlights up to 42 months of survival follow-up and 76 weeks of long-term NfL biomarker results from the HEALEY ALS Platform Trial.
  • The new treatment results provide evidence to support CNM-Au8 as a potential treatment for ALS, offering hope for improving the lives of patients with neurodegenerative diseases.
  • The clinical evidence of plasma neurofilament reduction and long-term improved survival results up to 3.5 years provides compelling insights into potential advancements in ALS treatment.

Impact - Why it Matters

This news matters because it provides clinical evidence of the potential of CNM-Au8 as a treatment for ALS. The long-term improved survival results and reduction in neurofilament levels offer hope for patients with neurodegenerative diseases, including ALS, Parkinson’s, and multiple sclerosis.

Summary

Clene (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. presented new long-term CNM-Au8 treatment results for survival and neurofilament light levels from the HEALEY ALS Platform Trial open label extension at the European Network for the Cure of ALS meeting. The data highlighted up to 42 months of survival follow-up and 76 weeks of long-term NfL biomarker results, showing a 28% reduction in biomarker NfL levels. The clinical evidence of plasma neurofilament reduction and long-term improved survival results compared to an established ALS dataset provides further evidence to support CNM-Au8 as a potential treatment for ALS.

Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. CNM-Au8 is an investigational first-in-class therapy that targets mitochondrial function and the NAD pathway while reducing oxidative stress. For more information, please visit www.Clene.com.

Source Statement

This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Inc. Presents New Long-Term CNM-Au8 Treatment Results at European ALS Meeting

blockchain registration record for the source press release.